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Abstract 
Epoxy resin monomers, including diglycidyl ethers of bisphenol A and F (DGEBA and 
DGEBF), are extensively used as building blocks for thermosetting polymers. However, they are 
known to cause widespread contact allergy. This research describes a number of alternative 
epoxy resin monomers, designed with the aim of reducing the skin sensitizing potency whilst 
maintaining the ability to form thermosetting polymers. The compounds were designed, 
synthesized, assessed for skin sensitizing potency using the in vivo murine local lymph node 
assay, and tested for technical applicability using thermogravimetric analysis and differential 
scanning calorimetry. All the novel epoxy resin monomers had decreased skin sensitization 
potencies compared to DGEBA and DGEBF. With respect to EC3 values, which is the estimated 
concentration of a substance required to induce a 3-fold increase in sensitization compared to a 
control, the best of the new monomers had a value approximately 2.5 times higher than those of 
DGEBA and DGEBF. The diepoxides were reacted with triethylenetetramine and four out of the 
six novel monomers gave polymers with a thermal stability comparable to that obtained with 
DGEBA and DGEBF. The new epoxy resin monomers have the potential to replace DGEBA and 
DGEBF, leading to a decreased incidence of contact allergy due to epoxy resins, decreased 
healthcare costs, and an increased quality of life for those handling thermosetting materials. 
Abbreviations 
BPA  Bisphenol A 
DGEBA Diglycidyl ether of bisphenol A 
DGEBF Diglycidyl ether of bisphenol F 
DSC  Differential scanning calorimetry 
ERM  Epxoy resin monomer 
ERS  Epoxy resin systems 
LLNA  Local lymph node assay 
mCPBA 3-Chloroperbenzoic acid 
TETA  Triethylenetetramine 
TGA  Thermogravimetric analysis 
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Introduction 
Epoxy resin systems (ERS) are commercial thermosetting products used in applications where 
strong, flexible, and light-weight construction materials are required. The global epoxy resin 
market is projected to reach over 3 million tons in annual sales by 2017.1 Traditionally used in 
paints, adhesives, coatings, industrial flooring and electrical laminates, they continually find new 
applications due to their excellent technical properties. Emerging usages include the relining of 
old pipes in buildings. ERS are multi-component systems comprised of epoxy resin monomers 
(ERMs), reactive diluents, hardeners and modifiers. ERMs are polymer precursor units which are 
reacted with hardeners to give the thermosetting product. The most commonly used ERMs are 
diglycidyl ethers based on bisphenol A (DGEBA) (also known as BADGE) and bisphenol F 
(DGEBF or BFDGE) (Figure 1). 
ERMs are among the most common causative agents of occupational ACD.2, 3 They are known 
to be extremely sensitizing to the skin and can sensitize upon first contact.4 ACD has been 
reported from various epoxy resin system components,5-13 most commonly from exposure to 
DGEBA and DGEBF.14, 15 DGEBA is included in the European baseline series for diagnosis of 
ACD.16 We are interested in ERS from a healthcare perspective as they are known to be 
extremely sensitizing to the skin. Contact allergy to epoxy resins is widespread in dermatitis 
patients with a reported prevalence ranging from 0.9 to 2.3%.17-20 Reported prevalences in 
occupational settings are higher, with between 11.7 and 12.5% of cases of allergic contact 
dermatitis (ACD) attributable to epoxy chemicals.21 Studies from workplaces found 
exceptionally high rates of ACD from ERS in aircraft manufacturing workers (56%)7 and marble 
workers (45%)22, amongst others. Skin sensitization is also common amongst construction 
workers (up to 9.7%) and is caused by ERS present in cement and other building materials,18, 23 
but is also frequent in newer settings such as the production of wind turbine rotor blades15 and 
relining of old pipes.13 It can also occur in unexpected settings such as microscopy of 
histological samples, due to the presence of ERS in the microscopy immersion oil.24, 25 Epoxy 
chemicals are also implicated in non-occupational contact allergy.17, 26 Skin sensitization 
potential has been investigated experimentally in vivo in mice and guinea pigs for DGEBA,27, 28 
DGEBF28, 29 and others.30, 31 DGEBA and DGEBF are classified as strong sensitizers in both 
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species according to regulatory guidelines.32 It would be highly advantageous to replace these 
strongly sensitizing ERMs with less hazardous alternatives. 
Our research aims to reduce the adverse skin sensitizing effects of ERMs whilst maintaining 
their excellent ability to form thermosetting polymers. This is a challenging task in which it is 
vital to keep a certain level of reactivity in order to enable polymerization. We have previously 
shown that the sensitizing effects of the epoxy resin DGEBF are directly related to the presence 
of the terminal epoxide groups.33 In the present study, compounds that incorporate terminal 
epoxy groups with reduced reactivity have been designed by alteration of the total chemical 
structure of the ERMs (1-6, Figure 1). The polymerization potential of the novel ERMs 1-6 was 
evaluated using differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). 
The skin sensitizing potency was assessed using the in vivo murine local lymph node assay 
(LLNA).34 
Experimental Procedures 
Caution: This study involves skin sensitizing compounds which must be handled with care. 
 
Instrumentation and Mode of Analysis. 1H and 13C NMR spectroscopy was performed on a 
Jeol Eclipse 400 spectrometer at 400 MHz and 100 MHz, respectively, using CDCl3 (residual 
CHCl3 δ 7.26 and δ 77.0 as internal standards) or DMSO-d6 (residual (CH3)2SO δ 2.54 and δ 
40.45 as internal standards) solutions. Electron-ionization mass spectral analysis (70 eV) was 
performed on a Hewlett-Packard 5973 mass spectrometer connected to a gas chromatograph 
(Hewlett-Packard 6890). The GC was equipped with a cool on-column capillary inlet and an HP-
5MSi fused silica capillary column (30 m×0.25 mm, 0.25 µm, Agilent Technologies, Palo Alto, 
CA). Helium was used as carrier gas, and the flow rate was 1.2 mL/min. The temperature 
program started at 70 °C for 1 min, increased by 10 °C/min for 20 min, and ended at 270 °C for 5 
min. For mass spectral analysis, the mass spectrometer was used in the scan mode detecting ions 
with m/z values from 50 to 1500. 
 
High performance liquid chromatography/mass spectrometry (LC/MS) analyses were performed 
using electrospray ionization (ESI) on a Hewlett-Packard 1100 HPLC/MS. The system included 
a vacuum degasser, a binary pump, an autoinjector, a column thermostat, a diode array detector, 
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and a single quadrupole mass spectrometer. The HPLC was equipped with a HyPURITY C18 
column (150×3 mm i. d., particle size 3 µm, Thermo Hypersil-Keystone, Thermo Electron Corp., 
Bellafonte, PA). The mobile phase consisted of 0.005% pentafluoropropanoic acid, 0.1% acetic 
acid, and 5% acetonitrile in water (solvent A) and 0.005% pentafluoropropanoic acid, 0.1% 
acetic acid, and 50% water in acetonitrile (solvent B). A linear gradient from 0% to 100% B over 
20 min, followed by 10 min of isocratic elution was used. The flow rate was 0.4 mL/min and the 
column temperature was 40 °C. The electrospray interface was used with the following spray 
chamber settings: nebulizer pressure, 40 psig; capillary voltage, 3500 V; drying gas temperature, 
350 °C; and drying gas flow rate, 10 L/min. Fragmentor voltage was set to 120 V. The mass 
spectrometer was used in scan mode detecting molecular ions with m/z values ranging from 50 to 
2000. 
 
DGEBA and DGEBF were purchased from Sigma-Aldrich; DGEBF was obtained as a mixture 
of three isomers. Sodium hydride (60% dispersion in mineral oil) was washed twice with hexane 
and dried with N2 prior to use. Acetone was purchased from Merck (Darmstadt, Germany) and 
olive oil from Apoteket AB (Goteborg, Sweden). Unless otherwise indicated, reagents were 
obtained from commercial suppliers and were used without further purification. TLC was 
performed using silica gel coated aluminum plates. The purity of all test compounds was >98% 
(GC/MS) before evaluation in biological assays. 
 
Chemical Synthesis  
 
Synthesis of bis[4-(2,3-epoxypropoxy)cyclohexyl]methane (2) (Scheme 1) 
4,4’-Methylenedicyclohexanol (2a). A solution of 4,4'-methylenediphenol (0.05 M solution in 
isopropanol) was reacted in an H-cube® continuous flow hydrogenation reactor (ThalesNano©) 
at 100 °C, 100 bar at a flow rate of 1 mL/min and employing 5% Ru/C (30 mm CatCart™) as 
catalyst. The reaction was monitored by TLC until the starting material was consumed. The 
solvent was evaporated in vacuo and aqueous NaOH solution (50 mL, 10% w/v) was added. The 
mixture was stirred for 10 min and extracted twice with ethyl acetate (50 mL). The organic 
fraction was reduced in vacuo and the white residue was recrystallized from diethyl ether to give 
compound 2a in 98% yield as a white powder (mixture of isomers).  
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1H NMR (DMSO-d6) δ 0.77-0.87 (m, 2H), 0.98-1.39 (m, 12H), 1.52-1.54 (m, 2H), 1.62 (m, 2H), 
1.76-1.79 (m, 2H), 3.27-3.31 (m, 1H), 3.71 (m, 1H), 4.21 (d, 1H, J=2.9 Hz), 4.44 (d, 1H, J=4.4 
Hz); 13C NMR (DMSO-d6) δ 27.7, 27.8, 31.9, 32.6, 33.2, 33.9, 34.1, 36.0, 40.6, 65.4, 69.8; EI-
MS (70 eV), m/z (%) 194 (2.6), 176 (29), 165 (12), 147 (16), 135 (18), 94 (69), 81 (100) 
Bis[4-(allyloxy)cyclohexyl]methane (2b). Sodium hydride (20.8 mmol, 5.2 equiv.) was washed 
with hexane (20 mL×2), suspended in anhydrous THF (40 mL) and cooled to 0 °C. Compound 
2a (4 mmol) was dissolved in anhydrous THF (20 mL) and added to the suspension. The mixture 
was stirred at 0 °C for 10 min. Allyl bromide (10.4 mmol, 2.6 equiv.) was added and the mixture 
was stirred at room temperature for 90 min before refluxing overnight. The reaction was 
continued until TLC indicated disappearance of the starting material. The mixture was cooled to 
0 °C and saturated aqueous NH4Cl (70 mL) was added slowly to quench the reaction. The 
aqueous layer was extracted with ethyl acetate (70 mL×3). The combined organic fractions were 
washed with brine (150 mL), dried over anhydrous Na2SO4 and reduced in vacuo. The product 
2b was isolated by column chromatography (9:1 hexane: ethyl acetate) and was obtained as a 
colorless oil in 93% yield. 
1H NMR (CDCl3) δ 0.80-0.89 (m, 2H), 0.99-1.43 (m, 12H), 1.71-1.82 (m, 4H), 1.99-2.03 (m, 
2H), 3.16-3.23 (m, 1H), 3.52 (m, 1H), 3.93 (d, 2H), 3.97-4.00 (m, 2H), 5.10-5.14 (m, 2H), 5.22-
5.28 (m, 2H), 5.85-5.96 (m, 2H); 13C NMR (CDCl3) δ 27.7, 29.5, 31.7, 32.4, 33.6, 33.9, 43.5, 
44.1, 68.8, 69.1, 73.7, 73.9, 78.0, 78.1, 116.1, 116.4, 135.7, 135.9; EI-MS (70 eV), m/z (%) 291, 
235 (3), 193 (10), 177 (100), 135 (23), 95 (79), 81 (80), 67 (31), 55 (38) 
Bis[4-(2,3-epoxypropoxy)cyclohexyl]methane (2). Compound 2b (1.4 mmol) was dissolved in 
chloroform (20 mL) and cooled to 0 °C. 3-Chloroperbenzoic acid (mCPBA) (≤77%, 2.6 mmol) 
was added and the mixture was stirred at 0 °C for 2 h. The mixture was then stirred at room 
temperature with addition of further mCPBA as necessary until complete on TLC. Aqueous 
NaOH (10% w/v) (40 mL) was added and extracted with CH2Cl2 (40 mL). The organic phase 
was washed with brine, dried over anhydrous Na2SO4 and reduced in vacuo. The product 2 was 
isolated as a mixture of isomers by column chromatography (9:1 hexane: ethyl acetate) as a 
colorless oil in 76% yield. 
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1H NMR (CDCl3) δ 1.12 (t, 2H, J=6.6 Hz), 1.22-1.31 (m, 4H), 1.34-1.42 (m, 10H), 1.78-1.81 (m, 
4H), 2.60 (dd, 2H, J=2.9, 5.1 Hz), 2.78 (dd, 2H, J=4.0, 5.1 Hz), 3.10-3.14 (m, 2H), 3.37-3.41 (m, 
2H), 3.53 (m, 2H), 3.61 (d, 1H, J=3.3 Hz), 3.64 (d, 1H, J=3.3 Hz); 13C NMR (CDCl3) δ 27.6, 
29.3, 29.5, 33.2, 42.7, 44.7, 51.3, 68.6, 75.0; EI-MS (70 eV), m/z (%) 324 (M+), 193 (10), 176 
(33), 147 (10), 135 (21), 113 (15), 95 (83), 81 (100), 67 (29), 57 (24) 
Synthesis of 2,2-bis[4-(2,3-epoxypropoxy)cyclohexyl]propane (1) (Scheme 1) 
2,2-Bis[4-(allyloxy)cyclohexyl]propane (1b) was prepared from commercially available 2,2-
bis(4-hydroxycyclohexyl)propane (1a) by the same method used to prepare 2b from 2a. The 
product 1b was isolated a mixture of isomers by column chromatography (9:1 hexane: ethyl 
acetate) as a colorless oil in 93% yield.  
 
1H NMR (CDCl3) δ 0.68 (s, 6H), 0.94-1.03 (m, 3H), 1.12-1.38 (m, 8H), 1.67-1.71 (m, 3H), 1.94-
1.96 (m, 1H), 2.02-2.08 (m, 3H), 3.15-3.20 (m, 1.5H), 3.49-3.56 (m, 0.5H), 3.92-3.94 (m, 1H), 
3.98-4.00 (m, 3H), 5.10-5.14 (m, 2H), 5.22-5.24 (m, 1H), 5.26-5.28 (m, 1H), 5.85-5.96 (m, 2H); 
13C NMR (CDCl3) δ 20.7, 21.0, 25.1, 30.8, 32.9, 36.7, 36.9, 43.1, 43.4, 44.0, 68.7, 69.0, 72.6, 
78.1, 78.2, 116.0, 116.5, 135.7, 135.9; EI-MS (70 eV), m/z (%) 204 (13), 181 (4), 139 (7), 123 
(100), 109 (8), 95 (10), 81 (36), 67 (25) 
  
2,2-Bis[4-(2,3-epoxypropoxy)cyclohexyl]propane (1) was prepared from 1b by the same 
method used to prepare compound 2 from 2b. The product 1 was isolated as a mixture of isomers 
by column chromatography (8:2 hexane: ethyl acetate) as a colorless oil in 82% yield. 
1H NMR (CDCl3) δ 0.69 (d, 6H, J=4.7 Hz), 0.94-1.04 (m, 3H), 1.10-1.39 (m, 8H), 1.66-1.72 (m, 
3H), 1.96 (m, 1H), 2.06-2.09 (m, 3H), 2.58-2.62 (m, 2H), 2.78 (t, 2H, J=4.8, 9.2 Hz), 3.10-3.15 
(m, 2H), 3.18-3.24 (m, 1.5H), 3.36-3.46 (m, 2H), 3.59-3.64 (m, 1H), 3.38-3.72 (m, 1.5H); 13C 
NMR (CDCl3) δ 20.7, 20.9, 25.0, 30.5, 30.8, 32.7, 32.9, 36.7, 36.9, 43.1, 43.4, 44.6, 44.7, 51.3, 
51.4, 68.5, 68.8, 73.8, 79.2, 79.3; EI-MS (70 eV), m/z (%) 204 (6), 197 (4), 155 (3), 123 (100), 
109 (14), 95 (14), 81 (37), 67 (23) 
 
Synthesis of bis[4-(3,4-epoxybutoxy)phenyl]methane (4) (Scheme 2) 
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Bis[4-(but-3-en-1-yloxy)phenyl]methane (4a). 4,4’-Methylenediphenol (5 mmol) was 
dissolved in DMF (20 mL) and K2CO3 (20 mmol, 4 equiv.) was added. 4-Bromo-1-butene (15 
mmol, 3 equiv.) was added. The mixture was warmed to 40 oC and stirred overnight. Water was 
added to quench the reaction. After extraction with EtOAc, the organic phase was washed with 
2M HCl, brine and dried over anhydrous Na2SO4. The product 4a was isolated using column 
chromatography (5:2 hexane: EtOAc) (61%) and used in the next step without further 
characterization. 
1H NMR (CDCl3) δ 2.49-2.54 (m, 4H), 3.84 (s, 2H), 3.98 (t, 4H, J=6.6 Hz) 5.07-5.17 (m, 4H), 
5.84-5.92 (m, 2H), 6.80 (d, 4H, J=8.4 Hz), 7.06 (d, 4H, J=8.4 Hz); EI-MS (70 eV), m/z (%) 308 
(100) (M+), 254 (19), 200 (19), 107 (34), 55 (37) 
Bis[4-(3,4-epoxybutoxy)phenyl]methane (4). Compound 4a (1.4 mmol) was oxidized using 
mCPBA (≤77%, 2.6 mmol) as described above for 2b. The product 4 was isolated by column 
chromatography (8:2 hexane: ethyl acetate) as a white powder in 52% yield. 
1H NMR (CDCl3) δ 1.88-1.96 (2H, m), 2.03-2.12 (2H, m), 2.56-2.58 (m, 2H), 2.81 (t, 2H, J=4.6 
Hz), 3.11-3.16 (m, 2H), 3.85 (s, 2H), 4.03-4.12 (m, 4H), 6.81 (d, 4H, J=8.8 Hz), 7.07 (d, 4H, 
J=8.8 Hz); 13C NMR (CDCl3) δ 32.6, 40.2, 47.2, 49.9, 64.7, 114.5, 129.9, 133.9, 157.1; EI-MS 
(70 eV), m/z (%) 340 (100) (M+), 269 (9), 199 (19), 107 (43), 71 (23)  
 
Synthesis of 2,2-bis[4-(3,4-epoxybutoxy)phenyl]propane (3) (Scheme 2) 
2,2-Bis(but-3-en-1-yloxy)phenyl]propane (3a) was prepared from 2,2-bis(4-
hydroxyphenyl)propane by the same method used to prepare compound 4a. The product 3a was 
isolated using column chromatography (5:2 hexane: EtOAc) (19%). 
1H NMR (CDCl3) δ 1.63 (s, 6H), 2.50-2.56 (m, 4H), 3.99 (t, 4H, J=6.6 Hz), 5.08-5.19 (m, 4H), 
5.85-5.95 (m, 2H), 6.80 (d, 4H, J=8.8 Hz), 7.13 (d, 4H, J=8.8 Hz); 13C NMR (CDCl3) δ 31.2, 
33.8, 41.8, 67.2, 113.9, 117.0, 127.8, 134.7, 143.3, 156.8; EI-MS (70 eV), m/z (%) 336 (35) 
(M+), 321 (100), 267 (20), 213 (26), 119 (8) 
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2,2-Bis[4-(3,4-epoxybutoxy)phenyl]propane (3) was prepared from compound 3a by the same 
method used to prepare compound 4 from compound 4a. The product 3 was isolated by column 
chromatography (8:2 hexane: ethyl acetate) as a white powder in 37% yield. 
1H NMR (CDCl3) δ 1.63 (s, 6H), 1.91-1.97 (m, 2H), 2.04-2.12 (m, 2H), 2.57-2.59 (m, 2H), 2.81-
2.83 (m, 2H), 3.13-3.17 (m, 2H), 4.06-4.12 (m, 4H), 6.81 (d, 4H, J=9.2 Hz), 7.14 (d, 4H, J=9.2 
Hz); 13C NMR (CDCl3) δ 31.1, 32.6, 41.8, 47.2, 49.9, 64.6, 113.9, 127.8, 143.4, 156.6; EI-MS 
(70 eV), m/z (%) 368 (19) (M+), 353 (100), 283 (5), 213 (8), 119 (5) 
Synthesis of bis[4-(2,3-epoxypropyl)phenyl]methane (6) (Scheme 3) 
Bis[(4-trifluoromethylsulfonyloxy)phenyl]methane (6a). 4,4’-Methylenediphenol (4.5 mmol) 
and anhydrous CH2Cl2 (50 mL) were added to a round-bottomed flask containing pyridine (18 
mmol, 4 equiv.) under an inert atmosphere. Trifluoromethanesulfonic anhydride (10.8 mmol, 2.4 
equiv.) dissolved in anhydrous CH2Cl2 (10 mL) was added dropwise to the reaction mixture at 0 
°C. The mixture was allowed to warm to room temperature and stirred for 1 h. The mixture was 
diluted with diethyl ether (40 mL), quenched with 10% aq. HCl (20 mL) and washed 
successively with saturated NaHCO3 (40 mL) and brine (40 mL). It was dried over anhydrous 
Na2SO4, the solvent was removed in vacuo and the product 6a was isolated using silica gel (95:5 
hexane: ethyl acetate) as a white solid in 93% yield. 
1H NMR (CDCl3) δ 4.03 (s, 2H), 7.22-7.23 (m, 8H); 13C NMR (CDCl3) δ 40.5, 118.8 (q, 3F, 
J=320 Hz), 117.2, 120.4, 121.7, 130.7, 140.6, 148.3; EI-MS (70 eV), m/z (%) 464 (95) (M+), 331 
(100), 315 (28), 198 (25), 181 (13), 169 (37), 153 (59), 141 (41), 115 (23) 
Bis(4-(2,3-epoxypropyl)phenyl)methane (6). A solution of 6a (0.86 mmol), Pd(PPh3)4 (0.17 
mmol, 0.2 equiv.) and allylSnBu3 (2.75 mmol, 3.2 equiv.) in anhydrous DMF (2 mL) was reacted 
in a microwave cavity at 160 ˚C for 30 min. The mixture was filtered through Celite with ethyl 
acetate (50 mL). The filtrate was stirred with KF (aq.) (50 mL) for 1 h. The mixture was filtered. 
The organic phase was separated, washed with brine (50 mL) and dried over anhydrous Na2SO4. 
The solvent was removed in vacuo and the residue was crudely purified by column 
chromatography (100% hexane) to yield bis(4-allylphenyl)methane (6b). Compound 6b (1.4 
mmol) was dissolved in chloroform (20 mL) and cooled to 0 °C. mCPBA (≤77%, 2.6 mmol) was 
added and the mixture was stirred at 0 °C for 2 h. The mixture was then stirred at room 
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temperature with addition of further mCPBA as necessary until complete on TLC. Aqueous 
NaOH (10% w/v) (40 mL) was added and extracted with CH2Cl2 (40 mL). The organic phase 
was washed with brine, dried over anhydrous Na2SO4 and reduced in vacuo. The product 6 was 
isolated by column chromatography (8:2 hexane: ethyl acetate) as a white solid in 28% yield. 
1H NMR (CDCl3) δ 2.53-2.55 (m, 2H), 2.75-2.80 (m, 4H), 2.86-2.91 (m, 2H), 3.12-3.15 (m, 2H), 
3.94 (s, 2H), 7.13-7.18 (m, 8H); 13C NMR (CDCl3) δ 38.5, 41.3, 47.0, 52.6, 129.1, 129.2, 134.9, 
139.6; EI-MS (70 eV), m/z (%) 280 (100) (M+), 249 (80), 237 (35), 223 (16), 207 (18), 193 (39), 
178 (53), 165 (32) 
 
Synthesis of 2,2-bis[4-(2,3-epoxypropyl)phenyl]propane (5) (Scheme 3)  
2,2-Bis[(4-trifluoromethylsulfonyloxy)phenyl]propane (5a) was synthesized from 2,2-bis(4-
hydroxyphenyl)propane in 94% yield by the same method used to obtain 6a.  
1H NMR (CDCl3) δ 1.68 (s, 6H), 7.17 (d, 4H, J=8 Hz), 7.26 (d, 4H, J=8 Hz); 13C NMR (CDCl3) 
δ 30.8, 42.9, 120.5 (q, 3F, J=282 Hz), 121.1, 128.7, 147.8, 150.2; EI-MS (70 eV), m/z (%) 492 
(14) (M+), 477 (100), 344 (11), 267 (7), 251 (13), 211 (22) 
2,2-Bis[4-(2,3-epoxypropyl)phenyl]propane (5) was synthesized from 5a, via intermediate 5b, 
by the same method used to obtain 6 from 6a. The product 5 was isolated by column 
chromatography (8:2 hexane: ethyl acetate) as a white solid in 31% yield. 
1H NMR (CDCl3) δ 1.66 (s, 6H), 2.54-2.56 (m, 2H), 2.75-2.80 (m, 4H), 2.85-2.90 (m, 2H), 3.12-
3.16 (m, 2H), 7.13-7.18 (m, 8H); 13C NMR (CDCl3) δ 30.8 (CH3), 38.4 (CH2), 42.5 (CH2), 47.1, 
52.6, 127.0, 128.7, 134.5, 149.1; EI-MS (70 eV), m/z (%) 308 (15) (M+), 293 (100), 249 (4), 205 
(22), 191 (8), 115 (8), 91 (7) 
Experimental Animals. Female CBA/Ca mice, 8 or 9 weeks of age, were purchased from 
NOVA SCB Charles River, Germany. The mice were housed in “hepa” filtered air flow cages 
and kept on standard laboratory diet and water ad lib. The study was approved by the local ethics 
committee in Gothenburg.  
Skin Sensitizing Potential of ERMs in Mice. The local lymph node assay (LLNA)35 was used 
to assess the sensitizing potential. Mice in six groups of three animals in each were treated by 
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topical application on the dorsum of both ears with the test compound (25 µL) dissolved in 
acetone: olive oil (AOO) (4:1 v/v) or with the vehicle control. All solutions were freshly 
prepared for each application. Each compound was tested at five different concentrations. The 
test concentrations used were as follows: 1, 2: 0.05, 0.5, 5.0, 10 and 30% (w/v); 4, 6: 0.05, 0.5, 
5.0, 10 and 20% (w/v); Treatments were performed daily for three consecutive days (days 0, 1, 
and 2). Sham treated control animals received vehicle alone. On day 5, all mice were injected 
intravenously via the tail vein with [methyl-3H]thymidine (2.0 Ci/mmol, Amersham Biosciences, 
UK) (20 µCi) in phosphate-buffered saline (PBS, containing 137 mM NaCl, 2.7 mM KCl and 10 
mM phosphate buffer, pH 7.4) (250 µL). After 5 h the mice were sacrificed, the draining lymph 
nodes were excised and pooled for each group, and single cell suspensions of lymph-node cells 
in PBS were prepared using cell strainers (Falcon, BD labware, 70 µm pore size). Cell 
suspensions were washed twice with PBS, precipitated with TCA (5%) and left in the 
refrigerator overnight. The samples were then centrifuged, resuspended in TCA (5%) (1 mL) and 
transferred to scintillation cocktail (10 mL) (EcoLume, INC Radiochemicals, USA). The 
[methyl-3H]thymidine incorporation into DNA was measured by β-scintillation counting on 
Beckman LS 6000TA Instruments. Results are expressed as mean dpm/lymph node for each 
experimental group and as stimulation index (SI), i.e., test group/control group ratio. Test 
materials that at one or more concentrations caused an SI greater than 3 were considered to be 
positive in the LLNA. EC3 values (the estimated concentration required to induce an SI of 3) 
were calculated by linear interpolation. The sensitizing potency was classified to the following: 
≤0.2% w/v, extreme; >0.2 to ≤2% w/v, strong; >2% w/v moderate.32 For registration in REACH, 
the LLNA is the preferred method for measuring skin sensitization potential in animals.36, 37 
 
LLNA with non-pooled lymph nodes. Single-cell suspensions of the lymph nodes from 
individual mice were prepared and the [methyl-3H]thymidine incorporation was measured to 
investigate if a statistically significant difference in the sensitizing potency at equimolar 
concentrations of DGEBA and 5 could be demonstrated. The test concentration (0.064 M) of 
each compound was selected on the basis of results from the LLNA experiments with pooled 
lymph nodes on DGEBA and 6. The test compounds were dissolved in acetone:olive oil (AOO) 
(4:1 v/v), were topically applied (25 µL) on the dorsum of both ears to two groups of mice (n=12 
per group). A sham treated control group of 12 mice received vehicle alone. All solutions were 
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freshly prepared before application. Procedures and measurements were performed according to 
the normal LLNA method described above, but the draining lymph nodes were not pooled and 
single-cell suspensions from the lymph nodes of each mouse were treated separately. Results are 
expressed as dpm/lymph node for each animal and as stimulation index (SI), i.e. the ratio of 
individual test animal/mean of the control group. The non-parametric Mann-Whitney U test was 
used for statistical comparison between the two compounds. 
Polymerization procedure. The general polymerization reaction between ERMs and 
triethylenetetramine (TETA) is shown in Scheme 4. This reaction was used for DGEBA, 
DGEBF, and compounds 1-6. The diepoxide and TETA were thoroughly mixed for 2 min at 
room temperature, always at a two-to-one ratio of amino-hydrogens to epoxy groups, and the 
mixture was transferred to cavities of silicon embedding mold and placed in a vacuum 
desiccator. The mixture was degassed under vacuum for 10 min to remove acetone and trapped 
air. The cast resin was then cured at room temperature for 24 h followed by postcuring in an 
oven at 120 °C for 2 h. After the postcure, the oven was switched off and allowed to cool slowly 
to room temperature to avoid crack formation.  
Differential Scanning Calorimetry (DSC). DSC analyses were carried out on polymers 
prepared from DGEBA, DGEBF and compounds 2 and 4 using a Perkin–Elmer Model Pyris 1 
instrument under nitrogen purge. The polymers were heated from 20 to 220 °C at a rate of 10 
°C/min, then cooled to room temperature at a rate of 20 °C/min. The change in enthalpy (H) 
was determined from the upward scan. 
 
Thermogravimetric Analysis (TGA). The TGA analyses were performed on polymers prepared 
from DGEBA, DGEBF and all the new diepoxides using a Perkin–Elmer TGA 7 instrument 
under nitrogen purge. The polymers were heated from 20 to 600 °C at a rate of 10 °C/ min and 
the weight loss was determined for each sample as a function of temperature. 
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Results and Discussion  
To the best of our knowledge, this is the first time that novel DGEBA and DGEBF analogs are 
described that maintain the excellent technical properties of currently available ERMs while 
reducing their harmful allergenic effects. By modifying the intrinsic reactivity of ERMs, we have 
addressed the underlying causes of contact allergy to ERS.  We thereby hope to diminish the 
problem of ACD caused by ERS, especially in occupational settings. We have adopted a global 
approach incorporating medicinal chemistry and toxicology to design new ERMs. 
ERM Design and Synthesis 
The design was focused on alternatives to DGEBA and DGEBF as these are the most commonly 
used ERMs and are described as the main cause of epoxy allergy.21 Six novel ERMs (three of 
DGEBA and three of DGEBF) were synthesized and evaluated (ERMs 1-6, Figure 1). The new 
compounds were designed to reduce the reactivity of the terminal epoxide enough to decrease the 
skin sensitizing potency but without compromising the ability to polymerize. This functional 
group is necessary for the desirable polymerization properties of DGEBA and DGEBF but we 
have previously shown that the sensitizing effects of DGEBF are directly related to the presence 
of the terminal epoxide groups.33 Hence, the terminal epoxide group was retained but its 
reactivity decreased by alteration of other molecular features. Each novel ERM had slight 
structural modifications compared to DGEBA and DBEBF, designed to give delicately balanced 
structures capable of polymerization without excessive reactivity causing skin sensitization. 
ERMs 1-6 were designed based on previous work on the epoxy reactive diluent phenylglycidyl 
ether (PGE).31, 38 Structural modifications to PGE that were found to give reduced skin 
sensitization potency were incorporated into the new ERMs. ERMs 1 and 2 have cyclohexane 
rings instead of aromatic, compounds 3 and 4 have a 2-carbon aliphatic chain between the ether 
oxygen and the epoxide ring instead of a 1-carbon chain, and the ether oxygen is removed in 
compounds 5 and 6 (Figure 1).  
ERM 2 was synthesized in three steps from bisphenol F (Scheme 1). After hydrogenation of the 
two aromatic rings at 100 °C and 100 bar (step i), alkylation with allyl bromide in the presence 
of sodium hydride (step ii) and subsequent epoxidation with 3-chloroperbenzoic acid (mCPBA) 
(step iii) yielded the final product 2 in 69% overall yield. Hydrogenation was found to proceed 
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faster in isopropanol compared to ethanol.39 ERM 1 was synthesized from commercially 
available 4,4’-isopropylidenedicyclohexanol (hydrogenated bisphenol A, 1a) in an analogous 
manner (76% overall yield) (Scheme 1). Both 1 and 2 were obtained as cis/trans isomeric 
mixtures. 
ERMs 3 and 4 were synthesized in two steps from bisphenol A and bisphenol F, respectively 
(Scheme 2). Alkylation with 4-bromo-1-butene in the presence of base (step i) followed by 
epoxidation with mCPBA (step ii) gave the desired products 3 and 4 in overall yields of 7% and 
32%, respectively. Potassium carbonate was found to be a suitable base, whereas neither 
triethylamine nor sodium hydride were appropriate. DMF was found to be a superior solvent to 
both THF and methanol.  
It was initially intended to synthesize ERMs with a two-carbon aliphatic linker between the 
aromatic ring and the terminal epoxide group. 3-Butenyltributylstannane was synthesized from 
tri-n-butyltin chloride40 but attempts to couple it with bisphenol F were unsuccessful. Instead, 
allyltributylstannane was used to give compounds with a one-carbon linker. ERMs 5 and 6 were 
prepared from bisphenol A and bisphenol F respectively in three steps (Scheme 3). Triflation of 
the phenolic groups (step i) was followed by microwave-assisted Stille coupling to 
allyltributylstannane (step ii).41 Finally, 5 and 6 were obtained by epoxidation with mCPBA (step 
iii) in overall yields of 29% and 26%, respectively.  
Skin Sensitizing Potency Studies  
The murine local lymph node assay (LLNA) was used to assess the skin sensitizing potency of 
the compounds.42 LLNA results are expressed as EC3 values, which is the estimated 
concentration of a compound required to induce a 3-fold increase in sensitizing potency 
compared to a control. Compounds with lower EC3 values are more sensitizing. Our group has 
previously reported EC3 values for DGEBA and DGEBF of 1.24 and 1.13% w/v (0.036 M and 
0.036 M), respectively.28 This EC3 value for DGEBA is comparable to an independently 
published value of 1.5% w/v (0.044 M).43 Initially in this study, analogs of both DGEBA and 
DGEBF were assessed in the LLNA. However, as DGEBA and DGEBF have the same EC3 
values and related compounds 1 and 2 were found to have similar EC3 values (2.3% and 2.4% 
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w/v, equivalent to 0.065 M and 0.074 M respectively, Figure 2), further in vivo testing was 
carried out only on analogs of DGEBF (ERMs 4 and 6) due to ethical considerations.  
All four of the novel ERMs tested had reduced in vivo sensitizing potencies compared to 
DGEBA and DGEBF (Figure 2 and Supporting Information Table S1). The difference in the 
EC3 values of the two commercial products (DGEBA and DGEBF) and our four ERMs is 
illustrated in Figure 2.B. The EC3 value of ERM 6 was the highest (2.56% w/v; 0.091 M) 
indicating that this is the least sensitizing compound. The EC3 values of the other ERMs tested 
were approximately twice those of DGEBA and DGEBF, indicating that they are also less 
sensitizing. The four new ERMs are classified as moderate sensitizers (EC3>2% w/v) in 
accordance with regulatory guidelines in comparison to the commercially available monomers 
DGEBA and DGEBF which are classified as strong sensitizers (0.2<EC3≤2% w/v) (Figure 2).32  
To establish whether there was a statistically significant difference between the sensitizing 
potencies of the new ERMs and DGEBA, an extension of the LLNA using non-pooled lymph 
nodes was applied. This modified method was used in our previous work with epoxy resin 
analogs as well as in other studies by the group.38, 44 For ethical reasons, we did not want to 
repeatedly perform LLNA experiments and therefore only ERM 5 was compared with DGEBA. 
We chose to use the DGEBA analogue 5, structurally related to the least sensitizing DGEBF 
analogue 6, for this experiment as the sensitizing potencies of the pairs of DGEBA/F analogues 
tested in the ordinary LLNA with pooled lymph nodes were similar. Statistical analysis revealed 
that DGEBA was significantly more potent in inducing lymph node cell proliferation than 5 at 
the chosen concentration of 0.064 M. (P<0.0001, Figure 3 and Table S2, Supporting 
Information), indicating that DGEBA is significantly more sensitizing than 5.  
Examining the results of all LLNA in vivo experiments indicates that the newer ERMs are less 
skin sensitizing than DGEBA and DGEBF. The new ERMs are classified as moderate skin 
sensitizers in comparison to DGEBA and DGEBF, which are strong skin sensitizers.32 To our 
knowledge, these are the first reported ERMs that are only moderately sensitizing. This is also 
the first time that a combined medicinal chemistry/toxicology approach has been used to design 
ERMs specifically aimed at reducing contact allergy. A reduction in the incidence of ACD due to 
occupational and non-occupational contact with ERS could be obtained by use of alternative, less 
sensitizing ERMs such as these alternative compounds.  
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Polymers from the ERMs 
The thermal properties and suitability for polymerisation of the new ERMs were investigated. 
Epoxy resins were prepared from the novel ERMs using triethylenetetramine (TETA) as the co-
reactant (Scheme 4). TETA was chosen because it is commonly used as a curing agent for epoxy 
resins.45 The thermal properties of the epoxy resins were assessed using differential scanning 
calorimetry (DSC) and thermogravimetric analysis (TGA) and the results were compared to 
epoxy resins based on DGEBA and DGEBF, prepared with the same molar ratio of the 
components and under the same reaction conditions. 
The DSC results showed that the polymers prepared from ERMs 2 and 4, DGEBA and DGEBF 
had almost the same glass transition temperature (Tg), between 42 and 43.6 °C (Table S3, 
Supporting Information). A Tg value of 40-45 °C has previously been reported for an epoxy resin 
based on DGEBA/TETA with the same molar ratio. Thus, the DSC analyses demonstrated that 
the enthalpy involved in the phase transition was approximately the same for all the polymers, 
including the polymer based on the standard diepoxide DGEBA. Since the analyses did not 
reveal any differences in performance between the diepoxides, no more DSC experiments were 
performed.  It should be noted that the Tg of the epoxy resin increases linearly and reaches a peak 
at a one-to-one ratio of amino-hydrogen to epoxy groups. At higher molar ratios of TETA to 
epoxy monomer, the Tg decreases linearly again.
46  This has been explained as a plasticization 
effect caused by an excess of curing agent, i.e., TETA.47  
Figure 4 shows TGA thermograms of the epoxy resins investigated in this study. Thermal 
stability and degradation data of the epoxy resins (i.e. IDT, Ea, Tmax, and Rmax) are summarized in 
Table 1. Initial decomposition temperature (IDT) indicates the apparent thermal stability of the 
epoxy resin, i.e., the failure temperatures of the resin in processing and molding, and is 
determined from the onset of weight loss of the sample in the TGA thermogram. The activation 
energy (Ea) for the decomposition of the cured epoxy resins was calculated from the TGA 
thermogram through the integral method based on the Horwitz–Metzger equation.48, 49 The 
maximum weight loss rate (Rmax) and the temperature at maximum rate of weight loss (Tmax) 
were taken from the peak values of the differential thermograms. Epoxy resins based on DGEBA 
and DGEBF were used as controls. 
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Epoxy resins based on ERMs 1, 2, 5 and 6 showed somehow higher IDT and Tmax values and 
almost the same thermal stability profiles as the epoxy resins based on the control samples. This 
demonstrates that the reactivity with TETA was approximately the same for ERMs 1, 2, 5 and 6 
as for DGEBA and DGEBF and also that the degree of cross-linking obtained with these six 
ERMs was almost the same. The IDT of the epoxy resins based on ERMs 3 and 4 was 
considerably lower than the IDT obtained for the other epoxy resins, indicating that these two 
compounds would be less suitable as commercial replacements for DGEBA and DGEBF. One 
possible reason for the lower decomposition temperature of the compound 3- and 4-based epoxy 
resins could be higher reactivity of these monomers against TETA, resulting in a lower degree of 
cross-linking. The activation energy (Ea) of the epoxy resins based on 5 and 6 was of the same 
magnitude as for resins based on DGEBA and DGEBF (Table 1). Taken together, the TGA data 
indicate that from a polymerization point of view 5 and 6 are the preferred ERMs, both giving 
polymers with TETA with a thermal stability close to that obtained with the commercial 
diepoxides DGEBA and DGEBF.  
There has been much unresolved discussion about the health effects of bisphenol A (BPA), 
which is used in the production of DGEBA.50 The focus of our work was not to replace BPA but 
to reduce the skin sensitizing potency and the cause of epidemics in the factories where the 
ERMs DGEBA  and DGEBF are used. Nonetheless, it is worth noting that the new ERMs 1, 2, 5 
and 6 do not contain a bisphenolic core in their structures. Further research would be required to 
investigate the effects of these structural differences on the hormonal imbalances associated with 
BPA. 
All of the new monomers had higher EC3 values in the LLNA compared to DGEBA and 
DGEBF, indicating that they are less sensitizing. As a representative example, ERM 5 was 
shown to be significantly less sensitizing than DGEBA in vivo. ERMs 1, 2, 5 and 6 have 
excellent thermal properties comparable to DGEBA and DGEBF. Taking the toxicological 
results in combination with the study of their technical properties, ERMs 5 and 6 emerge as the 
best candidates for further development. The design and use of improved ERMs with lesser 
toxicological effects is an excellent way to tackle the problem of contact allergy to ERS, 
particularly in occupational settings. Other measures, such as legislation, education of workers 
and use of personal protective equipment, are important to minimize the risks of exposure, but 
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unfortunately these measures only address the effects of the problem rather than the cause. Our 
approach recognizes that the cause of the problem is the inherent reactivity of epoxy groups, and 
suggests a solution based on reducing the skin sensitization potencies of the occupational 
allergens used. Use of the novel ERMs reported in this paper, particularly ERMs 5 and 6, has the 
potential to decrease the incidence of ACD due to ERS, decrease the healthcare costs involved 
with the diagnosis and treatment of such allergies, and increase the quality of life for persons 
handling ERS-containing thermosetting materials. 
 
Conclusion 
The aim of this research was to investigate structural modifications to existing ERMs, DGEBA 
and DGEBF, with a view to reducing their sensitizing potency. A series of six novel ERMs was 
synthesized and found to have reduced sensitizing potency in in vivo models. The reduction in 
skin sensitizing potency was demonstrated to be statistically significant for compound 5 
compared to DGEBA. In a preliminary assessment of their technical polymerization properties, 
four of the six new monomers were found to be comparable to DGEBA and DGEBF. It is 
anticipated that these new ERMs, particularly compounds 5 and 6, will be useful as replacements 
for DGEBA and DGEBF in many occupational applications, reducing the risk of allergic contact 
dermatitis to those working with epoxy resin systems. 
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Tables 
Table 1. Thermal stability and degradation data of the ERMs from thermogravimetrtic 
analysis in nitrogen  
Test 
compound 
IDTa 
°C 
Tmaxb 
°C 
Rmaxc 
% / °C 
Ead 
KJ/mol 
DGEBA 358 382 -1.58 96 
DGEBF 336 389 -1.02 103 
1 378 400 -1.94 78 
2 381 395 -2.86 75 
3 296 321 -1.42 49 
4 291 312 -1.62 54 
5 376 404 -0.77 115 
6 373 431 -0.78 98 
 
aIDT= Initial decomposition temperature which was determined with the temperature of onset weight loss 
of the sample 
bTmax= Temperature at maximum rate of weight loss which was taken as the peak value of the differential 
thermogravimetric thermograms 
cRmax= Maximum weight loss rate or the slope of weight loss at Tmax  
dEa= Activation energy for the cured epoxy resins’ decomposition 
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Figure Legends 
Figure 1. Structures of bidentate ERMs DGEBA, DGEBF and compounds 1-6 
Figure 2.A. Results from the LLNA for bidentate ERMs. B. Enlarged portion showing 
concentrations from 0 to 0.2 M. Dose-response curves for DGEBA (■), DGEBF (▲), 1 (▼), 2 (♦), 4 
(●) and 6 (□). SI=stimulation index. EC3 values; DGEBA: 0.036 M; DGEBF: 0.036 M; 1: 0.065 M; 
2: 0.074 M; 4: 0.065 M and 6: 0.091 M 
Figure 3. Results from the modified LLNA experiment using single-cell suspensions of the local 
lymph nodes from individual mice. Statistical analysis using non-parametric Mann-Whitney U test 
showed that when using 0.064 M of either epoxide, DGEBA (□) was significantly more potent in 
inducing lymph node cell proliferation compared to 5 (○) (P<0.0001) 
Figure 4. Thermogravimetric thermograms showing % weight loss at increasing temperatures of 
epoxy resins based on different ERMs in N2. DGEBA and analogs: dashed lines; DGEBF and 
analogs: solid lines. DGEBA (---), DGEBF (
__
), 1 (---), 2 (
__
), 3 (---), 4 (
__
), 5 (---), 6 (
__
). 
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Scheme Legends 
Scheme 1. Synthesis of 1 and 2a 
aReagents and conditions: (i) H2, 5% Ru/C, isopropanol, 100 ˚C, 100 bar, until complete on TLC; (ii) NaH, THF, 0 
˚C, 10 mins, then CH2CHCH2Br, rt, 90 min, then reflux until complete on TLC; (iii) mCPBA, CHCl3, 0 ˚C then rt 
until complete on TLC 
Scheme 2. Synthesis of 3 and 4 a 
aReagents and conditions: (i) CH2CH(CH2)2Br, DMF, K2CO3, 40 ˚C, overnight; (ii) mCPBA, CHCl3, 0 ˚C then rt 
until complete on TLC 
Scheme 3. Synthesis of 5 and 6 a 
aReagents and conditions: (i) O(SO2CF3)2 CH2Cl2, 0 ˚C then rt, 1 h; (ii) Pd(PPh3)4, CH2CHCH2SnBu3, DMF, 160 
˚C, 30 min, microwaves; (iii) mCPBA, CHCl3, 0 ˚C then rt until complete on TLC 
Scheme 4. Polymerization of ERMs with TETA a 
aReagents and conditions: Acetone (if solid), rt, 20 min; vacuum, 10 min; rt, 24 h; 120˚C, 2 h 
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Table S1. Detailed results from the LLNA of ERMsa 
Compound 
Test Concentration 
[3H] Thymidine 
incorporation 
SI EC3 value 
(% w/v) (M) 
(dpm/lymph 
node) 
 (% w/v) (M) 
1     
Control 
0.05 
0.5 
5 
10 
30 
 
1.4 x 10-3 
0.014 
0.14 
0.28 
0.85 
340 
283 
247 
2188 
4597 
7605 
 
0.83 
0.73 
6.43 
13.51 
22.35 
2.29 0.065 
2     
Control 
0.05 
0.5 
5 
10 
30 
 
1.5 x 10-3 
0.015 
0.15 
0.31 
0.92 
232 
259 
254 
1300 
3883 
7969 
 
1.12 
1.10 
5.62 
16.78 
34.43 
2.39 0.074 
4     
Control 
0.05 
0.5 
5 
10 
20 
 
1.5 x 10-3 
0.015 
0.15 
0.29 
0.59 
531 
413 
1186 
2260 
1959 
3012 
 
0.78 
2.23 
4.26 
3.69 
5.67 
2.21 0.065 
6     
Control 
0.05 
0.5 
5 
10 
20 
 
1.8 x 10-3 
0.018 
0.18 
0.36 
0.71 
477 
217 
296 
2768 
4360 
6089 
 
0.46 
0.62 
5.81 
9.15 
12.69 
2.56 0.091 
 
aGroups of mice were treated with the test substance in five different concentrations, on the dorsum of both ears 
for three consecutive days. Control animals received the vehicle alone. On day five, all mice were injected 
intravenously with PBS (250 µL) containing 20 µCi of [methyl-3H]thymidine. After 5 h the mice were sacrificed, 
the draining lymph nodes were excised and pooled for each group, single cell suspensions of lymph-node cells 
were prepared, and the thymidine incorporation into DNA was measured by β-scintillation counting. The increase 
in thymidine incorporation relative to vehicle-treated controls was derived for each experimental group and 
recorded as stimulation index (SI). The EC3 values (the estimated concentration required to induce a SI of 3) were 
calculated using linear interpolation 
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Table S2. Detailed results from the modified LLNA of ERMs DGEBA and 5a 
 
Compound        Test  
concentrations 
 
(%) (M) 
   dpm/      
   lymph node SI 
No. of 
animals 
Control   238b 1 12 
5 1.85 0.064 363 1.5 1 
 1.85 0.064 182 0.76 1 
 1.85 0.064 292 1.2 1 
 1.85 0.064 236 0.99 1 
 1.85 0.064 238 1.0 1 
 1.85 0.064 249 1.1 1 
 1.85 0.064 466 2.0 1 
 1.85 0.064 344 1.4 1 
 1.85 0.064 363 1.5 1 
 1.85 0.064 356 1.5 1 
 1.85 0.064 344 1.4 1 
 1.85 0.064 483 2.0 1 
DGEBA 2.18 0.064 1226 5.2 1 
 2.18 0.064 1896 8.0 1 
 2.18 0.064 2418 10 1 
 2.18 0.064 2169 9.1 1 
 2.18 0.064 5867 25 1 
 2.18 0.064 1342 5.6 1 
 2.18 0.064 1589 6.7 1 
 2.18 0.064 2618 11 1 
 2.18 0.064 2289 9.6 1 
 2.18 0.064 880 3.7 1 
 
2.18 
2.18 
0.064 
0.064 
776 
815 
3.3 
3.4 
1 
1 
 
aThe local lymph node experiments were performed as described in the experimental procedures. The SI 
corresponds to the increase in [methyl-3H]thymidine incorporation into DNA of treated animals relative to the mean 
dpm/lymph node of the vehicle-treated controls. 
bMean dpm/lymph node. Individual values from controls: 162, 181, 145, 334, 344, 221, 290, 102, 309, 100, 404, 264 
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Table S3. Polymerization parameters and characteristics of different epoxy resins from DSC 
 Glass transition temperature 
Tg / °C 
Decomposition temperature  
TDecomposition (50%) / °C 
Epoxy resin based on DGEBA 43.3 427 
Epoxy resin based on DGEBF 42.0 404 
Epoxy resin based on 2 43.5 392 
Epoxy resin based on 4 43.6 323 
 
